Nevertheless, as [68Ga]Ga-PSMA-11 consistently co-localizes with contrast-enhancing tumour regions – presumed to reflect areas of blood–brain barrier (BBB) disruption [11], the overall efficacy of PSMA-based RLT may be limited by incomplete irradiation of infiltrating tumour cells located beyond the contrast-enhancing margins. This evidence concerns the gene FOLH1 and neoplasm.